Atropine for myopia control: what the drops do and what the numbers actually say

Key takeaways

Atropine measurably slows how fast a short-sighted eye lengthens, but the exact mechanism by which it does this is still not settled; the old idea that it works purely by relaxing focusing is now considered unlikely.
Concentrations from 1% down to 0.01% have all been tested. Lower concentrations (0.01% to 0.05%) are used most now because they carry far fewer side effects for only a modestly smaller effect.
The major trials do not all agree: the largest trial run outside Asia did not meet its main target for 0.02% atropine, and a European trial found a significant prescription benefit only in its White participants, not its non-White participants.
Stopping treatment is not free. Trial evidence shows eyes progress faster again after stopping, with a bigger rebound after the stronger doses, and there is still no settled age or rule for when it is safe to stop.
Atropine slows progression; it does not reverse short-sightedness, replace glasses, or prevent myopia starting in a child who is not yet short-sighted. It is a prescription medicine, used only under an eye doctor's examination and monitoring.

Half the parents who ask me about short-sightedness are not really asking about short-sightedness. They are asking about the drop. Someone at school, or a cousin, or a forum at midnight has mentioned atropine, and they want to know what it actually is, whether it works, and why the dose on one bottle is not the dose on another. The short version: it is a real, well-studied treatment, and the honest answer is more complicated than a single number.

I have already set out how atropine compares with spectacle and contact lens options in slowing myopia down: drops, lenses and the honest numbers, including the Hong Kong trial ladder most parents ask about first. This article does not repeat that ladder. It goes deeper into the drop alone: what it is thought to do, the full range of concentrations that have actually been tested, where the big trials disagree with each other, what happens if you stop, and the side effects that matter day to day.

What does the atropine drop actually do to the eye?

Nobody can tell you the precise mechanism yet, and I would be cautious of anyone who claims otherwise. Atropine blocks a type of receptor called muscarinic, which is why in high doses it dilates the pupil and stops the eye focusing up close. For years the working theory was that this relaxation of the focusing muscle was the reason it slowed myopia. Animal studies have since made that theory unlikely, because atropine still slows eye growth in eyes that cannot accommodate in the first place. Current research points to atropine acting on several other chemical pathways in the eye at once, none of them proven alone. What is not in doubt is the practical result: a nightly drop, over months, measurably slows how fast a short-sighted eye lengthens. Why it does that is still being worked out.

Why are there so many different strengths of the drop?

Because the search for a dose that works without unwanted side effects has taken twenty years and several major trials. The earliest large trial gave children 1% atropine, the strongest concentration used, nightly for two years. It slowed prescription change by roughly three quarters compared with a dummy drop and left the treated eyes barely longer than they started, but a third of that concentration's pupil widening and loss of near focus made daily life harder for some children. A follow-up trial then tested 0.5%, 0.1% and 0.01% against each other. The difference in effect between those three was small. The difference in side effects was not: allergic irritation of the eye or skin turned up repeatedly at 0.1% and 0.5%, and not at all at 0.01%. That is the trade-off in one sentence, and it is why 0.01% to 0.05% is where most current prescribing and research now sits, not because those concentrations do the most, but because they do enough for a much smaller cost.

Do the big trials actually agree with each other?

No, and a parent deserves to hear that plainly rather than see it smoothed over. The largest trial run outside Asia, across sites in North America and five European countries, set out to prove that 0.02% atropine worked better than a placebo drop over three years. It did not. That was the trial's own prespecified main measure, and it was not met. In the same trial, the lower 0.01% concentration did slow the prescription significantly, though that result came from a secondary comparison, not the trial's main question. A separate trial in a mostly White European population found that 0.01% atropine did not significantly slow the prescription overall after two years, only the rate of eye growth, and when the results were split by ethnicity the benefit on prescription reached significance in the White children in that trial and not in the non-White children in the same trial. None of this means atropine fails. It means the effect is smaller, less consistent and more dependent on the population studied than a single headline percentage suggests, which is exactly why a current pooled analysis of the whole field still rates the evidence for the lowest doses as low or very low certainty, even while it finds a real, measurable effect on average.

What side effects actually matter for a child using this drop?

Two, in practice, and both track with the strength of the drop rather than being random. Light sensitivity, because the pupil widens and lets in more light, and blur at close range, because the drop briefly weakens the eye's ability to focus up close. Both were negligible at the lowest concentration tested and considerably more noticeable at the higher ones in the same trials, alongside occasional allergic redness or itching around the eye or eyelid that appeared almost only at the higher concentrations. A pair of sunglasses on a bright day and, occasionally, reading glasses for close work handle most of what a child on the lowest concentration actually experiences. No trial in this line of research has reported a serious eye complication linked to the drop itself, but none of them followed children for more than a few years, and how consistently side effects and daily use were even recorded varies between trials. That is a real gap, not a reassurance dressed up as one.

If we start the drop, can we ever stop it?

Eventually, but not on a fixed timeline, and stopping is not free. The clearest evidence on this comes from a trial that deliberately took children off atropine for a year after two years of treatment. During that year off, every concentration group's eyes started progressing faster again, and the group that had been on the strongest dose caught up the fastest, so that most of those children needed to restart. The group that had been on the lowest dose progressed more slowly during the year off and needed to restart least often. Put plainly, a bigger effect while treating can mean a bigger rebound after stopping, which is the opposite of what a stronger dose sounds like it should buy you. The wider evidence base agrees there is still not enough data to say when stopping is safe for a given child, which is one more reason this stays a decision made with your child's own eye doctor, watching the measurements over time, rather than a rule you can apply at home.

Does the drop cure short-sightedness, or replace glasses?

No, on both counts, and I want to be direct about it because the drop is sometimes talked about as if it were. Atropine slows how fast a short-sighted eye's prescription changes. It does not reverse the short-sightedness already there, and every trial behind these numbers enrolled children who were already myopic, so none of them tested whether the drop prevents myopia starting in a child who does not yet have it. A child using the drop still needs glasses fitted and updated as usual, and the drop does not stand in for the outdoor time that has separate, real evidence for slowing progression before and alongside treatment; I cover that habit on its own in the outdoor time evidence, sized honestly. Atropine is also a prescription medicine, examined into and monitored by an eye doctor, never something bought or started without that examination.

Is atropine the right choice for my child specifically?

That is not a question this article, or any article, can answer for you. It depends on your child's age, how fast the prescription has been climbing, what else has already been tried, and what is actually available and registered where you live, which your child's eye doctor is best placed to tell you rather than a forum or a receipt from a friend's clinic. If your child already wears glasses, bring every old prescription to the appointment. Two dated numbers tell an eye doctor more about the trend than one reading taken today, and that trend, not a single strength of drop, is what decides whether treatment is worth starting at all. I go through what that first prescription conversation looks like in what happens when your child needs glasses.

Don't wait for a routine appointment if…

Your child is under about seven and already short-sighted, or the prescription has jumped sharply in under a year.
A child using atropine drops or any eye drops develops a red, painful or persistently light-sensitive eye, or a skin rash around the eye.
One eye is noticeably more short-sighted than the other, or vision will not sharpen fully with glasses.
An eye starts to turn in or out, having been straight before.
A strongly short-sighted child reports new floaters, flashes of light, or a shadow or curtain across part of the vision.

Common questions

What does the atropine drop actually do to slow short-sightedness?

It measurably slows how fast the eye lengthens, which is what drives the rising prescription, but the precise mechanism is still not fully understood. Atropine blocks muscarinic receptors and was once thought to work mainly by relaxing the eye's focusing muscle, but animal studies suggest that is unlikely to be the main reason, and current research points to several receptor pathways acting together rather than one confirmed mechanism.

Why are there so many different strengths of atropine drop, from 0.01% up to 1%?

Twenty years of trials have looked for the smallest dose that still works well. The strongest, 1%, gave the largest effect in early trials but caused more glare and near blur. A later trial found the difference in effect between 0.5%, 0.1% and 0.01% was small, while allergic side effects appeared repeatedly at the higher two and not at 0.01%, which is why lower concentrations are used most now.

Do all the major atropine trials actually agree with each other?

No. The largest trial run outside Asia, across North American and European sites, did not meet its own main target for 0.02% atropine against placebo over three years, though 0.01% did show a significant benefit as a secondary result in the same trial. A separate European trial found a significant prescription benefit only in its White participants and not its non-White participants. The effect is real on average but not identical across every trial or population.

What side effects actually matter for a child using the drop day to day?

Mainly light sensitivity, because the pupil widens, and some blur at close range, because focusing is briefly weakened. Both are usually negligible at the lowest concentrations and more noticeable at higher ones, alongside occasional allergic redness or itching that appears mostly at higher concentrations. Sunglasses and, occasionally, reading glasses manage most of what a child on a low concentration experiences.

If my child starts atropine, can we ever stop it?

Eventually, but there is no fixed age, and stopping is not free. In the clearest trial on this, eyes progressed faster again after atropine was stopped, with the biggest rebound in the children who had been on the strongest doses. There is still not enough evidence to say when stopping is safe for a particular child, which makes this a decision to make with your child's own eye doctor rather than on a timeline.

Does atropine cure short-sightedness or mean my child won't need glasses?

No to both. Atropine slows the rate of change; it does not reverse short-sightedness already present, and every trial behind these results enrolled children who were already myopic, so none of them tested whether it prevents myopia starting. A child using the drop still needs glasses fitted and updated as usual.

Can I just buy atropine drops myself, or ask a shop for them?

No. Atropine is a prescription medicine used for myopia control only after an eye doctor has examined your child and is monitoring the treatment. It is not something to start, source or stop without that examination, whatever concentration is being discussed.

Is atropine definitely the right treatment for my child?

That depends on your child's age, how quickly the prescription has been changing, what else has already been tried, and what is actually available where you live, all of which your child's own eye doctor is best placed to weigh after an examination. Bring every old prescription to the appointment; the trend across readings matters more than any single number.

References

Optometry and Vision Science 2025 · Topical review: Potential mechanisms of atropine for myopia control · pubmed.ncbi.nlm.nih.gov
Ophthalmology 2006 · Atropine for the Treatment of Myopia 1 (ATOM1), randomised placebo-controlled trial of 1% atropine · pubmed.ncbi.nlm.nih.gov
Ophthalmology 2012 · Atropine for the Treatment of Myopia 2 (ATOM2), safety and efficacy of 0.5%, 0.1% and 0.01% doses · pubmed.ncbi.nlm.nih.gov
Ophthalmology 2016 · Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2 (ATOM2), including the treatment-cessation washout phase · pubmed.ncbi.nlm.nih.gov
Ophthalmology 2019 · Low-Concentration Atropine for Myopia Progression (LAMP) Study, phase 1 randomised placebo-controlled trial · pubmed.ncbi.nlm.nih.gov
JAMA Ophthalmology 2023 · Efficacy and Safety of 0.01% and 0.02% Atropine for Pediatric Myopia Progression Over 3 Years (CHAMP) · pubmed.ncbi.nlm.nih.gov
Acta Ophthalmologica 2024 · Myopia Outcome Study of Atropine in Children (MOSAIC), two-year result in a European population · pubmed.ncbi.nlm.nih.gov
Cochrane Database of Systematic Reviews 2025 · Interventions for myopia control in children: a living systematic review and network meta-analysis · pubmed.ncbi.nlm.nih.gov

By Dr Chan Li Yen. General information only. It does not replace a consultation. If you are worried about your child's eyes or vision, please see an eye doctor.